Premium
1α,25‐(OH) 2 D 3 Use on Psoriasis and Ichthyosis
Author(s) -
Okano Masaki
Publication year - 1991
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1991.tb05885.x
Subject(s) - psoriasis , ichthyosis vulgaris , medicine , dermatology , ichthyosis , epidermis (zoology) , atopic dermatitis , anatomy , filaggrin
The present work compared the clinical efficacy of topically applied 1α,25‐dihydroxyvitamin D 3 (1α,25‐(OH) 2 D 3 ) in 16 cases with psoriasis vulgaris, 5 with ichthyosis vulgaris and 8 with X‐linked ichthyosis. Sixty‐nine percent of the psoriatic cases responded to 1α,25‐(OH) 2 D 3 therapy, whereas no ichthyotic patients responded. The present study confirms the previously suggested effectiveness of the active form of vitamin D 3 for psoriasis and denies its possible efficiency against the ichthyoses. Direct suppression of hyperproliferative activity of the psoriatic epidermis is considered one of the most plausible mechanisms of 1α,25‐(OH) 2 D 3 efficacy, through examination of the aforementioned evidence.